A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults
Clinical trial NCT05903118 · COMPLETED
Trial details
- NCT number
- NCT05903118
- Sponsor
- Argorna Pharmaceuticals Co., LTD
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-08
- Primary completion
- 2022-09-01
- Enrollment
- 480
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.